Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent <i>Clostridioides difficile</i> Infection in a Randomized Clinical Trial

This study examines adverse events and durability of response of SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, compared with placebo for Clostridioides difficile infection.